The stock is still down more than 20% from the start of the year through yesterday’s close, taking a massive hit after its botched rollout of a copycat Wegovy pill.
Source: Sherwood News.

The stock is still down more than 20% from the start of the year through yesterday’s close, taking a massive hit after its botched rollout of a copycat Wegovy pill.
Source: Sherwood News.
Leave a Reply